| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1136-1144.)
© 2005 American Heart Association, Inc.
Heart Failure |
From Experimental and Molecular Cardiology/CARIM, University of Maastricht, the Netherlands (S.H., B.S., Y.M.P.); Molecular and Vascular Biology and Center for Transgene Technology and Gene Therapy, University of Leuven (S.H., P.V., F.G., H.G., P.C., S.J.), and the Departments of Cardiovascular Surgery (P.H., W.F.) and Cardiology (F.V.d.W., S.J.), University Hospital of Leuven, Belgium; and the Herz-und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Erich und Hanna Klessmann-Institut für Kardiovaskuläre Forschung und Entwicklung, Bad Oeynhausen, Germany (H.M., A.K.).
Correspondence to Stephane Heymans, MD, PhD, Experimental and Molecular Cardiology Laboratory/CARIM, Department of Cardiology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands. E-mail s.heymans{at}cardio.unimaas.nl
Received October 27, 2004; revision received April 22, 2005; accepted May 16, 2005.
Background— Alterations in the balance of matrix metalloproteinases (MMPs) and their specific tissue inhibitors (TIMPs) are involved in left ventricular (LV) remodeling. Whether their expression is related to interstitial fibrosis or LV dysfunction in patients with chronic pressure overload–induced LV hypertrophy, however, is unknown.
Methods and Results— Therefore, cardiac biopsies were taken in 36 patients with isolated aortic stenosis (AS) and in 29 control patients without LV hypertrophy. Microarray analysis revealed significantly increased mRNA expression of collagen types I, III, and IV and transcripts involved in collagen synthesis, including procollagen endopeptidase and lysine and proline hydroxylases, in AS compared with control patients. Collagen deposition was greater in AS than in control patients and was most pronounced in AS patients with severe diastolic dysfunction. Cardiac mRNA expression of TIMP-1 and TIMP-2 was significantly increased in AS compared with control patients (mRNA transcript levels normalized to GAPDH: TIMP-1, 0.67±0.1 in AS versus 0.37±0.08 in control patients; TIMP-2, 9.5±2.6 in AS versus 1.6±0.4 in control patients; P<0.05 for both) but did not differ significantly for MMP-1, -2, or -9. Cardiac TIMP-1 and -2 transcripts were significantly related to the degree of interstitial fibrosis and proportional to diastolic dysfunction in AS patients.
Conclusions— Cardiac expression of TIMP-1 and TIMP-2 is significantly increased in chronic pressure-overloaded human hearts compared with controls and is related to the degree of interstitial fibrosis.
Key Words: metalloproteinases remodeling hypertrophy hypertension collagen
This article has been cited by other articles:
![]() |
M. Franz, A. Berndt, A. Altendorf-Hofmann, N. Fiedler, P. Richter, J. Schumm, M. Fritzenwanger, H. R. Figulla, and B. R. Brehm Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy Eur J Heart Fail, November 1, 2009; 11(11): 1057 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsumoto, I.-K. Park, and K. Kohyama Matrix Metalloproteinase (MMP)-9, but Not MMP-2, Is Involved in the Development and Progression of C Protein-Induced Myocarditis and Subsequent Dilated Cardiomyopathy J. Immunol., October 1, 2009; 183(7): 4773 - 4781. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Weidemann, S. Herrmann, S. Stork, M. Niemann, S. Frantz, V. Lange, M. Beer, S. Gattenlohner, W. Voelker, G. Ertl, et al. Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis Circulation, August 18, 2009; 120(7): 577 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y-Y Lam, M J Mullen, M G Kaya, M A Gatzoulis, W Li, and M Y Henein Left ventricular long axis dysfunction in adults with "corrected" aortic coarctation is related to an older age at intervention and increased aortic stiffness Heart, May 1, 2009; 95(9): 733 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Szalay, M. Sauter, M. Haberland, U. Zuegel, A. Steinmeyer, R. Kandolf, and K. Klingel Osteopontin: A Fibrosis-Related Marker Molecule in Cardiac Remodeling of Enterovirus Myocarditis in the Susceptible Host Circ. Res., April 10, 2009; 104(7): 851 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schafer, P. Ellinghaus, W. Janssen, F. Kramer, K. Lustig, H. Milting, R. Kast, and M. Klein Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling Cardiovasc Res, April 1, 2009; 82(1): 30 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Duisters, A. J. Tijsen, B. Schroen, J. J. Leenders, V. Lentink, I. van der Made, V. Herias, R. E. van Leeuwen, M. W. Schellings, P. Barenbrug, et al. miR-133 and miR-30 Regulate Connective Tissue Growth Factor: Implications for a Role of MicroRNAs in Myocardial Matrix Remodeling Circ. Res., January 30, 2009; 104(2): 170 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Klein, R. T. Schermuly, P. Ellinghaus, H. Milting, B. Riedl, S. Nikolova, S. S. Pullamsetti, N. Weissmann, E. Dony, R. Savai, et al. Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling Circulation, November 11, 2008; 118(20): 2081 - 2090. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition Circ Heart Fail, November 1, 2008; 1(4): 249 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. West, P. J. Nestel, A. C. Kirby, R. Schnabel, D. Sullivan, R. J. Simes, C. Pollicino, E. Lubos, T. F. Munzel, H. D. White, et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study Eur. Heart J., April 1, 2008; 29(7): 923 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zittermann, S. S. Schleithoff, C. Gotting, O. Dronow, U. Fuchs, J. Kuhn, K. Kleesiek, G. Tenderich, and R. Koerfer Poor outcome in end-stage heart failure patients with low circulating calcitriol levels Eur J Heart Fail, March 1, 2008; 10(3): 321 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Crocker, R. F. Frausto, J. K. Whitmire, N. Benning, R. Milner, and J. L. Whitton Amelioration of Coxsackievirus B3-Mediated Myocarditis by Inhibition of Tissue Inhibitors of Matrix Metalloproteinase-1 Am. J. Pathol., December 1, 2007; 171(6): 1762 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. Lam, M. G Kaya, W. Li, V. S Mahadevan, A. A Khan, M. Y Henein, and M. Mullen Effect of endovascular stenting of aortic coarctation on biventricular function in adults Heart, November 1, 2007; 93(11): 1441 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. Lam, M. G. Kaya, O. Goktekin, M. A. Gatzoulis, W. Li, and M. Y. Henein Restrictive Right Ventricular Physiology: Its Presence and Symptomatic Contribution in Patients With Pulmonary Valvular Stenosis J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1491 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Paulus, C. Tschope, J. E. Sanderson, C. Rusconi, F. A. Flachskampf, F. E. Rademakers, P. Marino, O. A. Smiseth, G. De Keulenaer, A. F. Leite-Moreira, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur. Heart J., October 2, 2007; 28(20): 2539 - 2550. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Schroen, J. J. Leenders, A. van Erk, A. T. Bertrand, M. van Loon, R. E. van Leeuwen, N. Kubben, R. F. Duisters, M. W. Schellings, B. J. Janssen, et al. Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy J. Exp. Med., May 14, 2007; 204(5): 1227 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Kumbar, A. VanBergen, C. Ocampo, S. Muangmingsuk, A. J. Griffin, and M. Gupta Adapter molecule DOC-2 is differentially expressed in pressure and volume overload hypertrophy and inhibits collagen synthesis in cardiac fibroblasts J Appl Physiol, May 1, 2007; 102(5): 2024 - 2032. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fisch, S. Gray, S. Heymans, S. M. Haldar, B. Wang, O. Pfister, L. Cui, A. Kumar, Z. Lin, S. Sen-Banerjee, et al. Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy PNAS, April 24, 2007; 104(17): 7074 - 7079. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Quackenbush Microarray analysis and tumor classification. N. Engl. J. Med., June 8, 2006; 354(23): 2463 - 2472. [Full Text] [PDF] |
||||
![]() |
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload Hypertension, April 1, 2006; 47(4): 711 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Janssens and H. R. Lijnen What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res, February 15, 2006; 69(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |